CGT4859

CGT4859 is a small-molecule drug developed by Cogent Biosciences. Its target is FGFR2 (the sponsor names FGFR2, FGFR3). The sponsor states: A selective FGFR2/3 inhibitor designed to target tumours with genetic alterations in these fibroblast growth factor receptors. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in biliary tract cancer. The largest, NCT06777316, plans to enrol 110 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.